Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study-Reference-Cited by-同舟云学术

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

Published:2018-08-30 Issue:3 Volume:60 Page:675-684
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Walewski Jan¹,Paszkiewicz-Kozik Ewa¹,Borsaru Gabriela²,Hellmann Andrzej³,Janikova Andrea⁴,Warszewska Agnieszka¹,Mais Anna⁵,Ammendola Astrid⁵,Herz Thomas⁵,Krauss Babett⁵,Henning Stefan W.⁵

Affiliation:

1. Department of Lymphoid Malignancies, Maria Skłodowska-Curie Institute – Oncology Center, Warszawa, Poland;

2. Clinical Hospital Coltea, Bucharest, Romania;

3. Department for Hematology and Transplantology, University Clinical Centre, Medical University of Gdansk, Gdansk, Poland;

4. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic;

5. 4SC AG, Martinsried, Planegg, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1492122

Reference40 articles.

1. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond

2. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

3. The new therapeutical scenario of Hodgkin lymphoma

4. U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

5. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. HDAC inhibitors: Promising agents for leukemia treatment;Biochemical and Biophysical Research Communications;2023-11

3. 2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines;Bioorganic & Medicinal Chemistry;2023-10

4. Advances in Hodgkin’s lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors;Expert Opinion on Pharmacotherapy;2023-06-02

5. Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine;European Journal of Immunology;2023-02-23